Fig. 1 · Structure

Documents & Downloads

FPS-ZM1

Cat. No. A15806 CAS 945714-67-0

RAGE Antagonist

FPS-ZM1 inhibits Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells.

In Stock

Publications for FPS-ZM1

2 publications citing this product

  1. Ahana Banerjee, .et al. , Biomater Adv, 2024, Oct:163:213937 PMID: 38968788
  2. Ahana Banerjee, .et al. , Int J Biol Macromol, 2024, Jun;270(Pt 2):132384 PMID: 38754682

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

FPS-ZM1 inhibited Aβ40 binding to immobilized human soluble RAGE, with a reported Ki of 25 ± 5 nM. At 1 µM, it did not inhibit Aβ40/Aβ42 binding to soluble LRP in the comparator assay. [1]

Selectivity depends on concentration and assay. An independent 10 µM binding screen found off-target hits for FPS-ZM1, including androgen, peripheral benzodiazepine and κ-opioid sites; these single-concentration results do not establish functional potency. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
RAGE

In Vitro Studies

In RAGE-expressing CHO cells challenged with 1 µM Aβ40 for 4 h, FPS-ZM1 reduced lipid peroxidation measured as TBARS, with a reported EC50 of 11 ± 2 nM. This cellular endpoint is distinct from its binding inhibitory constant. [1]

Inhibition of amyloid-β binding to soluble RAGE

Biochemical assay · Immobilized human soluble RAGE; human soluble LRP comparator [1]

FPS-ZM1 inhibited radiolabeled Aβ40 binding to sRAGE. In a comparator assay it did not inhibit Aβ40 or Aβ42 binding to sLRP at 1 µM, whereas RAP inhibited binding. These receptor-specific comparisons do not establish universal target selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of 125I-Aβ40 binding to immobilized human sRAGEKi 25 ± 5 nM[1]
Aβ40 and Aβ42 binding to human sLRPComparator result No inhibition by FPS-ZM1 at 1 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10–500 nM FPS-ZM1 in the sRAGE/Aβ40 concentration-response assay; 1 µM in the sLRP comparator
Exposure duration
1 h for sRAGE binding; 2 h for sLRP ligand incubation
Method
Cell-free radioligand binding to immobilized sRAGE; ELISA for sLRP comparator
Vehicle
PBS binding medium; PBS vehicle in sLRP comparator
Co-treatment
5 nM 125I-Aβ40 in sRAGE assay; 100 nM Aβ40 or Aβ42 in sLRP comparator. FPS2 and RAP were separate comparator treatments.
Reported limits
The uncertainty of the fitted Ki is printed as ±5 nM; the caption gives mean ± SEM for the figure data, without separately defining fitted-parameter uncertainty.
Methods and source locations

Compound reported in the paper: FPS-ZM1; Compound label in the paper: FPS-ZM1

Evidence concerns the reported experimental material; it does not establish the identity or performance of an Adooq lot.

Figure 2A,D and caption; Methods: Binding of Aβ and other ligands to sRAGE; Binding of Aβ to LRP

Inhibition of 125I-Aβ40 binding to immobilized human sRAGE: 5 nM radioligand; FPS-ZM1 10–500 nM; 1 h at room temperature in PBS; no-inhibitor binding normalized to 100%. Caption reports data as mean ± SEM, n = 3–5 independent experiments; wells run in triplicate. — Figure 2A, printed fitted label; caption; Methods cell-free binding

Aβ40 and Aβ42 binding to human sLRP: ELISA with 100 nM Aβ40 or Aβ42 for 2 h at room temperature; PBS vehicle and RAP (1 µM) positive inhibition control. Figure comparison is marked NS; exact P values are not supplied in the caption. — Figure 2D; Results cell-free assays; Methods Binding of Aβ to LRP

Reduction of amyloid-β-induced lipid peroxidation in RAGE-CHO cells

Cell-based study · CHO cells expressing human RAGE, challenged with 1 µM Aβ40 [1]

FPS-ZM1 reduced Aβ40-induced TBARS in a concentration-response assay, with a reported EC50 of 11 ± 2 nM. This is a cellular lipid-peroxidation endpoint, not a receptor-binding IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Aβ40-induced thiobarbituric acid-reactive substancesEC50 11 ± 2 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Various FPS-ZM1 concentrations (concentration-response series); 1 µM Aβ40 challenge
Exposure duration
4 h
Method
Co-treatment in RAGE-expressing CHO cells; TBARS assay
Vehicle
0.05% DMSO
Co-treatment
Aβ40 is the experimental challenge; FPS2 was tested separately as a comparator.
Reported limits
The Methods do not enumerate the entire FPS-ZM1 concentration series for TBARS. Fit-specific uncertainty and endpoint-specific n within the caption range are not separately specified in the reviewed locations.
Methods and source locations

Compound reported in the paper: FPS-ZM1; Compound label in the paper: FPS-ZM1

Evidence concerns the reported experimental material; it does not establish the identity or performance of an Adooq lot.

Figure 2E and caption; Results Cell-based assays; Methods TBARS and Cell toxicity assay

Aβ40-induced thiobarbituric acid-reactive substances: Concentration-response inhibition following 4 h treatment with 1 µM Aβ40; TBARS assessed spectrophotometrically at 532 nm. Figure caption: mean ± SEM, n = 3–5 independent experiments. FPS2 comparator EC50 was 28 ± 6 nM; no fitted value inferred from the curve. — Figure 2E; Results Cell-based assays (EC50 sentence); Methods TBARS

Independent off-target binding screen at 10 µM

Biochemical assay · Cerep/Eurofins LeadProfilingScreen I; mixed human and rat target preparations [2]

At 10 µM, unlabeled FPS-ZM1 inhibited binding at several targets beyond RAGE. The screen is a concentration-specific selectivity limit; percentage inhibition does not establish functional antagonism or an IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Rat androgen receptor radioligand bindingInhibition at 10 µM 88.1%[2]
Rat peripheral benzodiazepine site radioligand bindingInhibition at 10 µM 84.9%[2]
Rat κ-opioid receptor radioligand bindingInhibition at 10 µM 81.7%[2]
Human adenosine A3 receptor radioligand bindingInhibition at 10 µM 64.4%[2]
Rat GABA-gated chloride channel radioligand bindingInhibition at 10 µM 61.9%[2]
Rat central benzodiazepine site radioligand bindingInhibition at 10 µM 58.7%[2]
Human melatonin MT2 receptor radioligand bindingInhibition at 10 µM 53.8%[2]
Human dopamine transporter radioligand bindingInhibition at 10 µM 48.8%[2]

Literature-Reported Treatment Conditions

Treatment concentration
1.0E-05 M (10 µM)
Method
LeadProfilingScreen I; percentage inhibition relative to control radioligand binding
Reported limits
Target-specific incubation times, vehicle, replicates and uncertainty are not supplied in the adopted Table S2 and its methods paragraph. No functional potency or low-concentration off-target claim is made.
Methods and source locations

Compound reported in the paper: FPS-ZM1; Compound label in the paper: FPS-ZM1

Evidence concerns the reported experimental material; it does not establish the identity or performance of an Adooq lot.

Sections 2.4 and 3.1.3; Table 1; Supplement FPS-ZM1 CEREP and Table S2

Rat androgen receptor radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Rat androgen receptor row; FPS-ZM1 CEREP methods paragraph

Rat peripheral benzodiazepine site radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Rat peripheral benzodiazepine site row; FPS-ZM1 CEREP methods paragraph

Rat κ-opioid receptor radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Rat κ-opioid receptor row; FPS-ZM1 CEREP methods paragraph

Human adenosine A3 receptor radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Human adenosine A3 receptor row; FPS-ZM1 CEREP methods paragraph

Rat GABA-gated chloride channel radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Rat GABA-gated chloride channel row; FPS-ZM1 CEREP methods paragraph

Rat central benzodiazepine site radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Rat central benzodiazepine site row; FPS-ZM1 CEREP methods paragraph

Human melatonin MT2 receptor radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Human melatonin MT2 receptor row; FPS-ZM1 CEREP methods paragraph

Human dopamine transporter radioligand binding: Percent inhibition of binding of a target-specific radiolabeled ligand. Authors use >50% inhibition or stimulation as the screen flag; values are single-concentration screen results. — Supplement Table S2, Human dopamine transporter row; FPS-ZM1 CEREP methods paragraph

In Vivo Studies

In a CT-2A glioma-resection mouse model, perioperative FPS-ZM1 (2 mg per injection, daily IP) reduced cerebral edema versus vehicle on postoperative day 1 (P = .03). The neurological SNAP-score comparison was not significant (P = .06). Comparator data were pooled across two experimental phases, and the model does not establish clinical efficacy. [3]

Perioperative FPS-ZM1 in a mouse glioma-resection model

Animal study · C57BL/6J mice bearing resectable orthotopic CT-2A gliomas [3]

Daily perioperative FPS-ZM1 reduced MRI-defined cerebral edema versus vehicle on postoperative day 1 (P = .03). Neurological scores favored FPS-ZM1, but the post hoc comparison did not reach significance (P = .06). The model used one glioma line and pooled comparator cohorts from two experimental phases.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cerebral edema volume on postoperative day 1Vehicle comparison P = .03; lower edema with FPS-ZM1[3]
SNAP neurological score on postoperative days 1, 3 and 7Post hoc vehicle comparison P = .06 (not statistically significant)[3]
Preoperative tumor and postoperative residual tumor volumesBaseline/resection comparison No significant differences among treatment groups[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
Day −4 to day +7 relative to tumor resection
Vehicle
10% DMSO, 40% PEG-300, 5% Tween-80, 45% PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
FPS-ZM1 perioperative monotherapy
2 mg per injection
Vehicle (100 µL IP; pooled n = 10); separate TTP488 and dexamethasone comparator arms each pooled n = 10Less cerebral edema on postoperative day 1 versus vehicle (P = .03); SNAP comparison P = .06.[3]
FPS-ZM1 perioperative monotherapy
Model: C57BL/6J mice with orthotopic CT-2A gliomas undergoing resection; n = 6
Reported limits: Dose is reported in mg, not mg/kg. Exact drug injection volume and sex are not established in reviewed locations.
Methods and source locations

Compound reported in the paper: FPS-ZM1; Compound label in the paper: FPS-ZM1

Evidence concerns the reported experimental material; it does not establish the identity or performance of an Adooq lot.

Methods Brain Tumor Resection Survival Surgery Model; Figure 2A–F; Results S20/S21; SDC1 Reagents and Cell Lines

Cerebral edema volume on postoperative day 1: Serial MRI with manual segmentation; mixed-effect model analysis and Dunnett post hoc test. FPS-ZM1 n = 6; pooled vehicle n = 10. Exact volume estimates are not digitized from bars. — Figure 2D and caption; Results RAGE Inhibitors Reduce CE After Brain Tumor Resection

SNAP neurological score on postoperative days 1, 3 and 7: Lower SNAP scores indicate better function. Caption reports overall two-way ANOVA F = 7.55, P = .002; this does not make the FPS-ZM1-versus-vehicle post hoc comparison significant. — Figure 2F and caption; Results RAGE Inhibitors Improve Postoperative Neurological Function

Preoperative tumor and postoperative residual tumor volumes: MRI volumetric assessment used to examine baseline tumor size and extent-of-resection confounding; exact comparison P values not reported in these locations. — Figure 2E and caption; Results S20

FPS-ZM1 perioperative monotherapy · Figure 2A,D,F and caption; Methods tumor-resection model; SDC1 Reagents and Cell Lines

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 945714-67-0
Applications RAGE Antagonist
Formula C20H22ClNO
Molecular Weight 327.85
SMILES
C1CCC(CC1)N(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 63 mg/mL (192.16 mM)
Water Insoluble
Ethanol 63 mg/mL (192.16 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
26 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. The Journal of clinical investigation (2012). PMID: 22406537 DOI: 10.1172/jci58642 Source material
  2. [2] Drake LR, Brooks AF, Stauff J, et al. Strategies for PET imaging of the receptor for advanced glycation endproducts (RAGE). Journal of pharmaceutical analysis (2020). PMID: 33133729 DOI: 10.1016/j.jpha.2020.07.009 Source material
  3. [3] Dayyani M, Filippov A, Zhang I, et al. RAGE Inhibition Reduces Surgery-Induced Cerebral Edema After Glioma Resection. Neurosurgery (2026). PMID: 41854274 DOI: 10.1227/neu.0000000000003987 Source material

Publications

2 publications citing this product

  1. Ahana Banerjee, .et al. , Biomater Adv, 2024, Oct:163:213937 PMID: 38968788
  2. Ahana Banerjee, .et al. , Int J Biol Macromol, 2024, Jun;270(Pt 2):132384 PMID: 38754682

Added to your cart

View Cart Checkout
Loading...